Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 85.18M shares rose 33.2% year over year, ahead of the +22.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +41.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.2% holds above the trailing-twelve-month pace of +22.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
85.18M+0.0% QoQ
Last fiscal yearDec 2025
72.95M+19.1% YoY
LTMMar 2026
78.18M+22.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.2%——
1 year+19.1%——
3-year CAGR+41.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
72.95M USD
Year-over-year change
+19.1%
4-year CAGR
+43.6%

Weighted Avg Shares (Diluted) vs competitors

How LRMR compares with its peers on the latest reported figures

  • LRMR's LTM Mar 2026 weighted avg shares (diluted) of 78.18M shares is the 5th highest of the 11 companies compared; the peer median is 62.69M shares.
  • Its year-over-year change of +22.5% is the 4th highest of 11, against a peer median of +11.3%.
  • Over three fiscal years its annual growth of +41.5% compares with a peer median of +21.5%.
LRMR Competitors Peer median
Weighted Avg Shares (Diluted) for LRMR and competitors
Company Period LTM YoY 3-year CAGR
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
ACIUAC Immune S.A.LTM Mar 202699.9M -0.5%+6.4%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
ENGNenGene Holdings Inc.LTM Apr 202659.85M +25.2%+47.9%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
KRROKorro Bio, Inc.LTM Mar 20269.94M +8.7%+232.7%
Peer median (excluding LRMR) 62.69M+11.3%+21.5%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development38.4M24.25M27.67M73.28M154.22M
Selling, General & Admin12.07M12.28M14.09M17.61M18.27M
Operating Expenses50.47M36.53M41.76M90.89M172.5M
Depreciation & Amortization326K318K311K318K350K
EBITDA(50.31M)(35.04M)(36.64M)(80.29M)(165.32M)
EBITDA Margin—————
Operating Income(50.47M)(36.53M)(41.76M)(90.89M)(172.5M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses(171K)1.17M4.81M10.29M6.82M
Income Before Tax(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Net Margin—————
EPS (Basic)(2.93)(1.33)(0.84)(1.32)(2.27)
EPS (Diluted)(2.93)(1.33)(0.84)(1.32)(2.27)
Weighted Avg Shares17.16M25.76M43.9M61.26M72.95M
Weighted Avg Shares (Diluted)17.16M25.76M43.9M61.26M72.95M

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.